Marc Bourliere
Overview
Explore the profile of Marc Bourliere including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
234
Citations
5293
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ramier C, Protopopescu C, Di Beo V, Parlati L, Marcellin F, Carrat F, et al.
Liver Int
. 2025 Mar;
45(4):e70065.
PMID: 40087922
Background And Aims: Early assessment of hepatocellular carcinoma (HCC) risk could improve long-term outcomes in people with chronic hepatitis B virus (HBV) infection. Some existing HCC predictive scores are not...
2.
Nahon P, Lusivika-Nzinga C, Merle P, Zoulim F, Decaens T, Ganne-Carrie N, et al.
J Hepatol
. 2025 Feb;
PMID: 40020929
Background And Aims: The objective was to describe the dynamics of noninvasive tests (NITs) in cirrhotic patients following sustained virological response (SVR) and to assess their correlation with hepatocellular carcinoma...
3.
van Bommel F, Verbinnen T, Agarwal K, Vanwolleghem T, Lampertico P, Buti M, et al.
Hepatol Commun
. 2025 Feb;
9(3).
PMID: 40008890
Background: In the nucleos(t)ide analog (NA)-control arm of the REEF-2 study (NCT04129554), virologic relapse (confirmed increase in HBV DNA >2000 IU/mL) and biochemical flare (ALT increases ≥3× upper limit of...
4.
Lam L, Bourliere M, Pol S, Carrat F
Aliment Pharmacol Ther
. 2024 Dec;
61(5):865-875.
PMID: 39737762
Background: Conflicting results have been reported on the impact of tenofovir versus entecavir on liver-related outcomes. Aims: To explore trends in clinical outcomes in chronic hepatitis B virus (HBV)-infected patients...
5.
Asselah T, Lampertico P, Aleman S, Bourliere M, Streinu-Cercel A, Bogomolov P, et al.
Liver Int
. 2024 Dec;
45(4):e16174.
PMID: 39648559
Background And Aims: The safety and tolerability of bulevirtide (BLV), a novel entry inhibitor of hepatitis delta virus, were evaluated in an integrated analysis of clinical trial results from patients...
6.
Nicolas C, Domas Q, Pol S, Bardou-Jacquet E, Loustaud-Ratti V, Metivier S, et al.
Liver Int
. 2024 Nov;
45(4):e16158.
PMID: 39530494
Background: Hepatitis C virus genotype 5 (HCV-GT-5) is found mainly in South Africa. In our area in central France, the prevalence of HCV-GT-5 is 14%. Methods And Results: Here we...
7.
Barre T, Parlati L, Bourliere M, Ramier C, Marcellin F, Protopopescu C, et al.
J Viral Hepat
. 2024 Sep;
31(12):830-846.
PMID: 39252600
Although Hepatitis C virus (HCV) infection can be cured with direct-acting antivirals (DAA), some cured patients face a serious risk of advanced liver damage and early mortality. In order to...
8.
Adhoute X, Bourliere M, Anty R
Ann Transl Med
. 2024 Aug;
12(4):59.
PMID: 39118945
No abstract available.
9.
Adhoute X, Gonzalez A, Levi-Strauss T, Mineur L, Penaranda G, Sellier F, et al.
Eur J Gastroenterol Hepatol
. 2024 Jul;
36(11):1329-1339.
PMID: 39083056
Background And Aims: The combination of atezolizumab plus bevacizumab (Atz/Bev) has radically changed the treatment strategy for advanced hepatocellular carcinoma (HCC) but raises questions. Our objectives were to determine survival...
10.
Neuzillet C, Decraecker M, Larrue H, Ntanda-Nwandji L, Barbier L, Barge S, et al.
Liver Int
. 2024 Jul;
44(10):2517-2537.
PMID: 38967424
Intrahepatic cholangiocarcinoma (iCCA) is the second most common malignant primary liver cancer. iCCA may develop on an underlying chronic liver disease and its incidence is growing in relation with the...